vs

Side-by-side financial comparison of MongoDB, Inc. (MDB) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MongoDB, Inc. is the larger business by last-quarter revenue ($628.3M vs $321.1M, roughly 2.0× MADRIGAL PHARMACEUTICALS, INC.). MongoDB, Inc. runs the higher net margin — -0.3% vs -18.2%, a 17.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 18.7%). MongoDB, Inc. produced more free cash flow last quarter ($141.8M vs $-133.8M).

MongoDB, Inc. is an American software company that develops and provides commercial support for the source-available database engine MongoDB, a database for unstructured data. Over the years, the company has expanded the product from its NoSQL roots to have broader appeal to enterprise customers, such as adding ACID and transactions.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

MDB vs MDGL — Head-to-Head

Bigger by revenue
MDB
MDB
2.0× larger
MDB
$628.3M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+192.1% gap
MDGL
210.8%
18.7%
MDB
Higher net margin
MDB
MDB
17.9% more per $
MDB
-0.3%
-18.2%
MDGL
More free cash flow
MDB
MDB
$275.7M more FCF
MDB
$141.8M
$-133.8M
MDGL

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
MDB
MDB
MDGL
MDGL
Revenue
$628.3M
$321.1M
Net Profit
$-2.0M
$-58.6M
Gross Margin
71.5%
Operating Margin
-2.9%
-18.6%
Net Margin
-0.3%
-18.2%
Revenue YoY
18.7%
210.8%
Net Profit YoY
79.5%
1.4%
EPS (diluted)
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDB
MDB
MDGL
MDGL
Q4 25
$628.3M
$321.1M
Q3 25
$591.4M
$287.3M
Q2 25
$549.0M
$212.8M
Q1 25
$548.4M
$137.3M
Q4 24
$529.4M
$103.3M
Q3 24
$478.1M
$62.2M
Q2 24
$450.6M
Q1 24
$458.0M
$0
Net Profit
MDB
MDB
MDGL
MDGL
Q4 25
$-2.0M
$-58.6M
Q3 25
$-47.0M
$-114.2M
Q2 25
$-37.6M
$-42.3M
Q1 25
$15.8M
$-73.2M
Q4 24
$-9.8M
$-59.4M
Q3 24
$-54.5M
$-107.0M
Q2 24
$-80.6M
Q1 24
$-55.5M
$-147.5M
Gross Margin
MDB
MDB
MDGL
MDGL
Q4 25
71.5%
Q3 25
71.0%
Q2 25
71.2%
Q1 25
72.8%
96.7%
Q4 24
74.4%
Q3 24
73.2%
Q2 24
72.8%
Q1 24
75.0%
Operating Margin
MDB
MDB
MDGL
MDGL
Q4 25
-2.9%
-18.6%
Q3 25
-11.0%
-39.7%
Q2 25
-9.8%
-22.2%
Q1 25
-3.4%
-57.8%
Q4 24
-5.3%
-64.8%
Q3 24
-14.9%
-187.1%
Q2 24
-21.8%
Q1 24
-15.5%
Net Margin
MDB
MDB
MDGL
MDGL
Q4 25
-0.3%
-18.2%
Q3 25
-8.0%
-39.8%
Q2 25
-6.9%
-19.9%
Q1 25
2.9%
-53.4%
Q4 24
-1.8%
-57.5%
Q3 24
-11.4%
-172.0%
Q2 24
-17.9%
Q1 24
-12.1%
EPS (diluted)
MDB
MDB
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-5.08
Q2 25
$-1.90
Q1 25
$-3.32
Q4 24
$-2.50
Q3 24
$-4.92
Q2 24
Q1 24
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDB
MDB
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$834.1M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$2.9B
$602.7M
Total Assets
$3.6B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDB
MDB
MDGL
MDGL
Q4 25
$834.1M
$198.7M
Q3 25
$647.1M
$295.7M
Q2 25
$657.8M
$186.2M
Q1 25
$490.1M
$183.6M
Q4 24
$673.1M
$100.0M
Q3 24
$1.3B
$232.7M
Q2 24
$815.7M
Q1 24
$803.0M
$622.5M
Total Debt
MDB
MDB
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
MDB
MDB
MDGL
MDGL
Q4 25
$2.9B
$602.7M
Q3 25
$2.9B
$625.7M
Q2 25
$3.0B
$696.0M
Q1 25
$2.8B
$710.6M
Q4 24
$1.5B
$754.4M
Q3 24
$1.4B
$777.2M
Q2 24
$1.3B
Q1 24
$1.1B
$850.8M
Total Assets
MDB
MDB
MDGL
MDGL
Q4 25
$3.6B
$1.3B
Q3 25
$3.5B
$1.4B
Q2 25
$3.6B
$1.0B
Q1 25
$3.4B
$996.6M
Q4 24
$3.2B
$1.0B
Q3 24
$3.1B
$1.1B
Q2 24
$3.0B
Q1 24
$2.9B
$1.1B
Debt / Equity
MDB
MDB
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDB
MDB
MDGL
MDGL
Operating Cash FlowLast quarter
$143.5M
$-133.5M
Free Cash FlowOCF − Capex
$141.8M
$-133.8M
FCF MarginFCF / Revenue
22.6%
-41.7%
Capex IntensityCapex / Revenue
0.3%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$346.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDB
MDB
MDGL
MDGL
Q4 25
$143.5M
$-133.5M
Q3 25
$72.1M
$79.8M
Q2 25
$109.9M
$-47.1M
Q1 25
$50.5M
$-88.9M
Q4 24
$37.4M
$-104.5M
Q3 24
$-1.4M
$-67.0M
Q2 24
$63.6M
Q1 24
$54.6M
$-149.2M
Free Cash Flow
MDB
MDB
MDGL
MDGL
Q4 25
$141.8M
$-133.8M
Q3 25
$71.6M
$79.0M
Q2 25
$108.3M
Q1 25
$24.6M
Q4 24
$35.5M
$-104.7M
Q3 24
$-2.4M
$-67.8M
Q2 24
$63.1M
Q1 24
$51.9M
$-149.5M
FCF Margin
MDB
MDB
MDGL
MDGL
Q4 25
22.6%
-41.7%
Q3 25
12.1%
27.5%
Q2 25
19.7%
Q1 25
4.5%
Q4 24
6.7%
-101.3%
Q3 24
-0.5%
-109.0%
Q2 24
14.0%
Q1 24
11.3%
Capex Intensity
MDB
MDB
MDGL
MDGL
Q4 25
0.3%
0.1%
Q3 25
0.1%
0.3%
Q2 25
0.3%
0.0%
Q1 25
4.7%
0.0%
Q4 24
0.4%
0.2%
Q3 24
0.2%
1.3%
Q2 24
0.1%
Q1 24
0.6%
Cash Conversion
MDB
MDB
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
3.19×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDB
MDB

Mongo DB Atlas Related$470.4M75%
Other Subscription$138.7M22%
Services$19.2M3%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons